Company
We are dedicated to studying neurodegenerative diseases and are at the forefront of Alzheimer’s research
From discovery, through development to clinical trials, regulatory submissions and product registration, our work aims to halt the progression of Alzheimer’s and other types of dementia.
Mission and values
Our mission is to discover, develop and commercialise innovative products for the diagnosis, treatment and cure of dementias caused through protein aggregation.
Our history
Since 2002, we have been on a journey of discovery that has led to global collaborations and thousands of people taking part in clinical trials.
Clinical trials
Clinical trials are critical to taking science from the laboratory to a point where we can help patients. Find out more about our trials and how they’ve advanced our understanding of how to treat neurodegenerative diseases.
Our product
Find out more about our pioneering drug, hydromethylthionine mesylate (HMTM), which could revolutionise treatment for Alzheimer’s and related diseases.
Collaborations
Global partnerships have been essential in allowing us to reach a stage where a possible treatment for Alzheimer’s disease could be made widely available. Find out how you can be part of our mission.
Our leadership team
With a wide range of scientific, medical and commercial backgrounds, our leadership team has the passion, drive and commitment to bring to market a drug that will ease the pain of millions around the world.